Esperion Therapeutics (NASDAQ: ESPR) reported Q3 EPS of ($0.16), $0.18 worse than the analyst estimate of $0.02. Revenue for the quarter came in at $87.3 million versus the consensus estimate of $92.5 million.

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.